Skip to Content

Experts Available to Discuss Study Showing Link Between High Levels of Estrogen and Breast Cancer Recurrence

(BUSINESS WIRE)--Mar 7, 2008 - ExpertSource:

TOPIC: A study, which appears in the journal Cancer, Epidemiology, Biomarkers and Prevention, shows women who experienced breast cancer recurrence had high levels of estrogen, despite the fact that many of them were taking anti-estrogen drugs, according to an article by Reuters. The study followed 3,088 women treated for early stage breast cancer who were cancer-free at the time of enrollment. Researchers found the levels of estrogen in women whose cancer returned was double the levels of those who remained cancer-free. While tamoxifen has been shown to reduce the risk of breast cancer recurrence by almost 50 percent, experts say breast cancer survivors should engage in moderate to vigorous exercise to lower estrogen levels.

EXPERTS: ExpertSource can offer several highly qualified experts to comment on this story:

Dr. John Link, director of breast medical oncology at Orange Coast Memorial Medical Center in Fountain Valley, CA, is recognized as one of the foremost breast cancer doctors in the world. He actively practices at Breastlink, the comprehensive breast cancer group he founded in 1995. He also conducts research, writes books and teaches. In 1998, he founded the Breast Cancer Care and Research Fund, a non-profit charity dedicated to educating and helping women achieve Optimal Care. He has been recognized by numerous organizations for his dedication and contributions to women with this disease. He went into the practice of medical oncology and taught at his alma mater. After several years in general oncology (cancer medicine), Dr. Link decided to dedicate his career to the care and cure of women with breast cancer. He founded one of the first "comprehensive breast cancer diagnostic and treatment centers" in the U.S. at Long Beach Memorial Medical Center in 1985. This center has been recognized as a leader and innovator in breast cancer care (Self Magazine and ABC's 20/20). He has authored two books for women with breast cancer: The Breast Cancer Survival Manual (Holt, 4th edition 2007) and Take Charge of Your Breast Cancer (Holt, 2002). His present goal is to continue to care for women with breast cancer and make a difference. He says, "We are putting together the best breast cancer treatment group possible that will give women 'optimal care' for their particular, unique situation. We will do this through our books, research, website and our center."

Dr. John Link was a principal investigator in the Women's Health Initiative clinical trial and can provide insight into the study.

His research and publications include: Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer. Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer (SWOG S0307) NSABP B-42 A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor(AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer. Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer (425-07) An open-label, multi-centre study of lapatinib in combination with chemotherapy in patients with ErbB2 overexpressing breast cancer after trastuzumab failure in the neoadjuvant or adjuvant setting (438-07).

PR Contact: Trace Longo


Dr. Ira Goldknopf, of Power3 Medical, has over 30 years of proteomic experience. Proteomics determine Breast Cancer, Parkinson's and Alzheimer's among other diseases. He is a well recognized pioneer and leader in Proteomics, having produced, the first isolation, identification and sequencing of a new protein spot on a 2D gel. He also discovered ubiquitin conjugation of proteins, which laid the groundwork for the 2000 Lasker award. He was cofounder of ProteEx in 2000 and prior to that was founding CEO of UbiquiTex Technologies, and cofounder and VP of R&D of FlowGenix Corporation. His experience also includes Manager GMP, QC/QA, and analytical operations, GAF/ISP and Triplex Pharmaceuticals. He spent 10 years on the faculty of Baylor College of Medicine and a sabbatical year at the Medical Nobel Institute, Karolinska Institute, Stockholm, Sweden. He is the author of more than 70 publications and also serves on the Scientific Advisory Board of the Company.

PR Contact: Janet Vasquez


ExpertSource cannot guarantee the immediate availability of these experts or their familiarity with this specific issue.

ExpertSource provides academic and industry experts to the media at no charge. Journalists are encouraged to submit queries to ExpertSource when seeking experts on specific subjects. An online registration form is available at


Business Wire ExpertSource Group
888/292-4446 or

Posted: March 2008